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OBJECTIVE: Macrolide antibiotics have anti-inflammatory properties in lung diseases. The aim of this study was to
investigate the effect of clarithromycin in pulmonary cellular inflammatory response in mice.
METHOD: Eight adult Swiss mice were studied. All animals received an intranasal challenge (80 µL) with dead
Pseudomonas aeruginosa (1.0 x 1012 CFU/mL). Bronchoalveolar lavage was performed 2 days later, with total cell count
and differential cell analysis. The study group (n = 4) received clarithromycin treatment (50 mg/kg/day, intraperitoneal) for
5 days. Treatment was initiated 2 days before intranasal challenge.
RESULTS: There was no significant difference in total cell count between the groups (mean: 2.0 x 106 and 1.3 x 106,
respectively). In both groups, there was a predominance of neutrophils. However, the study group had a higher percentage
of lymphocytes in the bronchoalveolar lavage than the control group (median of 19% vs 2.5%, P = .029).
CONCLUSION: Clarithromycin alters the cytological pattern of bronchoalveolar lavage of Swiss mice with neutrophil
pulmonary inflammation, significantly increasing the percentage of lymphocytes.
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Macrolides have been used for the
treatment of different bacterial infec-
tions. They are frequently prescribed
in clinical practice, particularly for res-
piratory infections. Erythromycin,
clarithromycin, and azithromycin are
the most common macrolides used,
and they are recognized as the first
line treatment for infections caused by
Mycoplasma sp., Chlamydia sp.,
Ureaplasma sp., and other bacteria.1
Recently, studies have been emerg-
ing demonstrating an anti-inflamma-
tory effect of these drugs in lung dis-
eases.2 Clinical trials have shown a
benefit of macrolide therapy in some
pulmonary disorders, such as diffuse
panbronchiolitis (DPB), asthma, and
cystic fibrosis.6-8
Macrolides may inhibit neutrophil
recruitment and interleukin (IL)-8 pro-
duction.3-5 Other studies have shown
that macrolides may inhibit corticos-
teroid metabolism and may increase
the treatment effect in asthmatic pa-
tients.7,9 However, the anti-inflamma-
tory mechanisms of macrolides in pul-
monary diseases are not fully under-
stood.
Little data has been published
about the effect of macrolides on cel-
lular inflammation in neutrophil-pre-
dominant lung disease in animal mod-
els. One previous study using mice
with chronic infection by Pseu-
domonas aeruginosa (P. aeruginosa)
and treated with clarithromycin has
demonstrated a reduction on
lymphocyte cell counts in
bronchoalveolar lavage (BAL).10 This
study, however, used live P.
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aeruginosa for inducing lung disease.
On the other hand, Sugiyama et al.
found no significant changes in differ-
ential cell counts of in vitro lipopoly-
saccharide (LPS)-stimulated BAL in
rats treated with erythromycin.11
The aim of this study is to analyze
the effect of clarithromycin on the pat-
tern of pulmonary cellular response in
BAL of mice with neutrophil-pre-
dominant lung disease that is induced
using dead P. aeruginosa.
METHOD
Animals
Eight adult (6 to 8 weeks old) male
Swiss mice from our University were
used. Animals were provided by the
University and were kept at Institute
during the study period.
Protocol for induction of neutrophil
pulmonary disease
The Microbiology Department
provided the P. aeruginosa sample in
a culture plate. After being scraped
from the plate, the sample was diluted
in phosphate-buffered saline (PBS), to
a concentration of 1 x 1012 CFU/mL.
All P. aeruginosa were frozen to –
20°C.
While under sedation, the animals
from both the study group (n = 4) and
control group (n = 4) received 1 intra-
nasal challenge (80 mL) with P.
aeruginosa solution.14,15 Sedation, per-
formed to allow pulmonary aspiration
of the instilled solution by suppress-
ing upper airway reflexes, consisted of
intraperitoneal administration of 0.1
mL of a solution of ketamine (0.4 mL),
xylazine (0.1 mL), and normal saline
(0.5 mL).
There was no control group with-
out P. aeruginosa in this study. The
authors of this study have previously
shown a significant induction of neu-
trophil-predominant lung disease in
mice using this protocol.13
Clarithromycin treatment
A dose of 15 mg/kg/day is used for
clinical treatment of infections in hu-
mans. Based on previous study
protocols14,15 in experimental models,
we used a dosage of 50 mg/kg/day.
The treatment was initiated 2 days be-
fore the intranasal challenge with P.
aeruginosa.
The study group received
clarithromycin treatment over a 5-day
period, with a single daily intraperito-
neal (i.p.) dose. The protocol used in
the study is illustrated in figure 1.
Bronchoalveolar lavage
Bronchoalveolar lavage was per-
formed 2 days after intranasal chal-
lenge. Mice were anesthetized with an
i.p. injection of 0.2 mL of the same
ketamine and xylazine solution that
was used at the intranasal challenge.
After anesthesia, a tracheotomy was
performed, with trachea cannulation
and tube fixation. One mL of normal
saline was instilled. After 5 seconds,
the material was aspirated. This proce-
dure was repeated 3 times with the
same solution.
Total cell count and differential
cytological test
The BAL was weighed and centri-
fuged (2,000 rpm for 2 minutes). The
precipitate was diluted in 1 mL of
PBS. Determination of TCC and cell
viability was performed in a Neubauer
chamber (Boeco, Germany), with
trypan blue staining.
For differential cytology, 40mL of
the sample was cytocentrifuged
(FANEM, São Paulo, Mod. 218), at
500 rpm, for 5 minutes. Slides were
fixed with methyl alcohol and stained
with May-Grunwald-Giemsa stain.
Cells were analyzed according to their
morphology. The cell types at light
microscopy were expressed as a per-
centage after counting 200 cells.
Statistical analysis
Values are described as mean and
median, and the statistical difference
was calculated using the Mann-
Whitney or t test, depending on the
sample distribution. Differences were
considered significant when P <.05.
Ethics
The study was approved by the
Ethics Committee for Animal Research
Figure 1 - Study protocol.
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of the Institution and was based on
animal models research guidelines.
RESULTS
The BAL was performed success-
fully in all studied mice. The mean of
returned volume of BAL was 66%.
Mice did not present adverse reactions
associated with clarithromycin treat-
ment.
The mean TCC in all mice studied
was 1.65 x 106 cells/mL. The mean
TCC of the study and the control
group were 2.01 x 106 cells/mL and 1.3
x 106 cells/mL, respectively. There was
no significant difference between the
groups.
All mice had increased neutrophil
counts in the BAL. The differential
cell count results are presented in ta-
ble 1. The study group had a signifi-
cantly higher percentage of
lymphocytes in the BAL compared
with the control group, with medians
of 19% and 2.5% (P = .029), respec-
tively (Fig. 2). Neutrophil counts were
not different between the groups stud-
ied (P = .097) (Fig. 3).
DISCUSSION
In the present study, the BAL of
mice having a neutrophilic pulmonary
disorder that was induced by dead P.
aeruginosa and treated with
clarithromycin had a significant in-
crease in the percentage of lymphocytes
compared with control group.
We used a small number of mice.
Since the groups are homogeneous
and the bias factors are smaller com-
pared with human studies, the practice
of using small numbers of animals is
usually sufficient.
The pulmonary inflammatory ab-
normalities in the BAL of mice follow-
ing aspiration of P. aeruginosa have
been previously described. Pinto et
Table 1 - Comparison of differential cell counts in the bronchoalveolar lavage
(BAL) between the groups studied.
All Control group Macrolide group
x 106 cells/mL % x 106 cells/mL % x 106 cells/mL %
Total cell count 1.30 100 1.21 100 1.29 100
Neutrophils 1.00 74.6 1.00 81.9 0.87 67.2
Lymphocytes 0.10 8.30 0.03 2.90 0.29 22.5
Macrophages 0.20 12.8 0.18 15.2 0.13 10.2
Figure 2 - Comparison of lymphocyte percentage in the bronchoalveolar lavage (BAL)between
the groups studied.
Figure 3 - Comparison of neutrophil percentage in the bronchoalveolar lavage (BAL) between
the groups studied.
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al.13 showed that mice with pulmonary
inflammation induced by dead P.
aeruginosa had an increase in TCC
and in the percentage of neutrophils in
the BAL. Thus, this experimental
model may be used for studies
analyzing the macrolide anti-inflam-
matory effect in neutrophilic pulmo-
nary diseases.
There are a few mechanisms that
may explain the anti-inflammatory ef-
fect of macrolides. Some studies have
shown a decreased neutrophil recruit-
ment to the lungs following treatment
with erythromycin. Kadota et al. dem-
onstrated this effect in mice that re-
ceived an intratracheal injection of li-
popolysaccharide.3 Furthermore, a de-
crease in neutrophil count, IL-8, and IL-
1 was observed in the BAL of patients
with DPB, who received treatment with
erythromycin or roxythromycin.5-12
Therefore, these drugs may inhibit neu-
trophil recruitment.4
Yanagihara et al. showed that mice
chronically infected by P. aeruginosa,
which have similar pathologic changes
to DPB, had a progressive reduction of
the lymphocyte count in the BAL
when treated with clarithromycin.10
However, in 1 previous study
analyzing cellular response in BAL
following lipopolysaccaride challenge
in rats treated with erythromycin, no
difference in differential cell percent-
age was detected.11 The present study
has shown an increased lymphocyte
percentage in the BAL of mice with
neutrophilic pulmonary disease and
treated with clarithromycin. Therefore,
our results demonstrate that
macrolides alter the differential cell
count in the BAL in this illness. How-
ever, our results should not be consid-
ered particularly an anti-inflammatory
effect of macrolides and should be in-
terpreted with caution. In spite of this
limitation, we speculate that macrolide
treatment could both stimulate an ear-
lier onset of an adaptive cellular re-
sponse or inhibit an acute neutrophilic
response (with a consequent increase
in lymphocyte percentage), resulting
in a quicker resolution of the airway
inflammation. On the other hand, the
increased number of lymphocytes in
the airways of the treated group could
be interpreted as a marker of increased
pulmonary inflammatory response.
Studies with a larger number of
animals may reveal more significant
alterations both in lymphocytic and
neutrophilic response. Moreover, the
bacterial concentration used for intra-
nasal challenge was very high (1x1012
CFU/mL). Studies with lower concen-
trations of P. aeruginosa in the intra-
nasal challenge may show greater ef-
fects of macrolides on the BAL.
Therefore, additional studies using
larger numbers of mice, lower concen-
trations of P. Aeruginosa, and includ-
ing the measurement of some
interleukin levels (IL-8, IL-10, or al-
pha-tumor necrosis factor) in the BAL
are essential for a better understanding
of the anti-inflammatory mechanisms
of these medications. Furthermore, the
present experimental model using
dead intranasal P. aeruginosa for in-
ducing neutrophil lung inflammation
have been shown to be low-cost and
effective and consequently should be
used for the development of further
studies with macrolides.
In conclusion, our study demon-
strates that macrolide treatment affects
lymphocyte response in the BAL of
mice with neutrophilic lung disease.
Further studies are required to better in-
vestigate the mechanisms of the anti-
inflammatory action of macrolides in
neutrophilic pulmonary diseases, which
will be useful in treatment of many
prevalent diseases with high morbidity.
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RESUMO
PINTO AL e col. Efeito da claritro-
micina na celularidade do lavado
broncoalveolar em camundongos
com doença pulmonar neutrofílica
induzida. Rev. Hosp. Clin. Fac.
Med. S. Paulo 59(3):99-103, 2004.
OBJETIVO: Os antibióticos
macrolídeos podem apresentar um efeito
antiinflamatório em doenças pulmona-
res. O objetivo deste estudo é investi-
gar o efeito da claritromicina na respos-
ta inflamatória celular pulmonar em ca-
mundongos Swiss. MÉTODO: Foram
utilizados 8 camundongos Swiss adul-
tos (6-8 semanas). Todos os animais re-
ceberam um desafio intranasal (80 µL)
com Pseudomonas aeruginosa mortas
(1 x 1012 UFC/mL). Dois dias após o de-
safio, foi realizado lavado bronco-
alveolar (LBA) com contagem total de
células (CTC) e exame citológico dife-
rencial. O grupo em estudo (n=4) rece-
beu tratamento com claritromicina
(50mg/kg/dia, intraperitoneal) por 5
dias, sendo iniciado o tratamento 2 dias
antes do desafio intranasal. O grupo
controle (n=4) não recebeu tratamento
com claritromicina. RESULTADOS:
Não houve diferença significativa na
CTC entre os grupos (média de 2x106
e 1,3x106, respectivamente). Em ambos
os grupos, houve predomínio absoluto
de neutrófilos. Contudo, o grupo trata-
do com claritromicina, apresentou um
número percentual significativamente
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maior de linfócitos no LBA (mediana
de 2,5% vs 19%, p=0,029). CONCLU-
SÃO: O uso de claritromicina altera o
exame citológico diferencial do lavado
bronco-alveolar de camundongos Swiss
com inflamação pulmonar neutrofílica,
aumentando significativamente o nú-
mero percentual de linfócitos.
UNITERMOS: Claritromicina,
Inflamação. Doenças pulmonares.
Modelos animais. Neutrófilo.
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